Clinical Characteristics and Side Effects of Multidrug Resistant Tuberculosis Therapy at Top Referral Hospital West Java Indonesia by Rahmawati, Rika Nurlaily et al.
Althea Medical Journal. 2016;3(4)
526     AMJ December 2016
Clinical Characteristics and Side Effects of Multidrug Resistant 
Tuberculosis Therapy at Top Referral Hospital West Java Indonesia
Rika Nurlaily Rahmawati,1 Emmy Hermiyanti Pranggono,2 Rovina Ruslami31Faculty of Medicine Universitas Padjadjaran, 2Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital Bandung, 3Department of Pharmacology and Therapy Faculty of Medicine Universitas Padjadjaran
Abstract
Background: The efficacy of multidrug resistant tuberculosis (MDR TB) therapy is still being questioned. 
It has lesser quality, longer duration therapy and high toxicity level. This study was conducted to identify 
clinical characteristics and side effect of MDR TB therapy at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia as the top referral hospital in West Java. 
Methods: A retrospective descriptive study was performed to 142 medical records of MDR TB inpatient 
and outpatient at Dr. Hasan Sadikin General Hospital from January 2012–July 2013. Data was collected 
on October–November 2013. Data about clinical characteristics and side effects of MDR TB therapy were 
collected and was analyzed in the form of percentage.
Results: From 142 patients, 96% had history of tuberculosis therapy. Eighty (56%) of them had positive 
acid fast bacilli (AFB) sputum that still remained after 5th month or more with category 2. Seventy (49%) 
patients used combination of pyrazinamide, capreomycin, levofloxacin, ethionamide and cycloserine (Pz-
Cm-Lfx-Eto-Cs). All patients experienced side effects during therapy and the majority of them (91%) had 
gastroenteropathy and rheumatism. Tentamen suicide was detected in one patient.  
Conclusions: The MDR TB patients had history of tuberculosis therapy. The majority of patients 
used combination of Pz-Cm-Lfx-Eto-Cs. All patients experienced side effects during MDR TB therapy. 
[AMJ.2016;3(4):526–32]
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Introduction
Multidrug resistant tuberculosis (MDR TB) is 
defined as tuberculosis infection that caused 
by resistant microorganism to isoniazid and rifampisin.1 It is global emergency case with 
approximately 3.7% of new case and 20% of previous tuberculosis case in 2011.1,2 There 
are 22.2 % of MDR TB cases in developing country.1,2 Actually, Indonesia is at the eight 
rank among 27 burden MDR TB countries.2 
Therapy of MDR TB has given 56−59% good prognosis.3,4 The most contributing factor is 
known as man made phenomenon, which included health care facilitators, medications and patients.3,5,6 The efficacy of MDR TB therapy, 
which uses category 4, is still questionable. The 
regimen has lesser quality and availability in 
health care. It is also more expensive and more 
side effects occur compare to other category.6 
Longer duration therapy and high toxicity level cause the patients uncompliance to therapy.
The spread of MDR TB cases is still unkown. 
Updates of research data regarding MDR TB are needed to evaluate the therapy outcomes. 
Registration of MDR TB patients at Dr. Hasan Sadikin General Hospital Bandung as the top referral hospital in West Jaca Indonesia, just started on January 2012. Therefore, 
The aim of this study was to identify clinical 
characteristics and side effects of MDR TB therapy at Dr. Hasan Sadikin General Hospital. 
Methods
A descriptional retrospective study was 
conducted to medical records of 142 patients 
with MDR TB, consisted of inpatients and 
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outpatients at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, on October–
November 2013. Data collection was performed on medical records from January 
2012–July 2013 (19 months data) that 
fullfilled the diagnosis of MDR TB, included sputum culture test and drug susceptibility 
test (DST). Variable were included in this study, comprised of clinical characteristics and 
side effects of MDR TB therapy. The clinical 
characteristics that defined as suspected 
criteria of MDR TB at early diagnosis were 
categorized into 8 categories:7 1) sputum that 
still remained positive of acid fast bacilli (AFB) 
during previous category 2 tuberculosis (TB) 
therapy at 5th month or more; 2) sputum that still remained positive of AFB during previous category 2 TB therapy at 3rd month or more; 
3) sputum that still remained positive of AFB during previous category 1 TB therapy at 5th 
month or more; 4) sputum that still remained positive of AFB during previous category 1 
with additional 1 month TB therapy; 5) history 
of tuberculosis therapy for >1 month in non-
directly observed treatment short-course 
(DOTS) facility, using second line regimen, 
such as fluoroquinolone and kanamycin; 6) 
default case; 7) relapse case (category 1 or 2); 
and 8) close contact to MDR TB patients. 
Therapy of MDR TB was defined as anti 
tuberculosis category 4 regimen therapy of 
MDR TB patients at Dr. Hasan Sadikin General 
Hospital. The therapy was categorized into 
3, namely 1) pyrazinamide, kanamycin, 
levofloxacin, ethionamide, cycloserine (Z-Km-
Lfx-Eto-Cs); 2) pyrazinamide, kanamycin, 
levofloxacin, ethionamide, cycloserine, 
ethambutol (Z-Km-Lfx-Eto-Cs-E) and 3) 
pyrazinamide, levofloxacin. ethionamide, 
cycloserine, capreomycin (Z-Lfx-Eto-Cs-
Cm). Side effects of MDR TB therapy defined 
as side effect that occurred during MDR TB 
therapy. Data were analyzed in the form of percentage This study had been approved by 
Health Research Ethics Committee, Faculty of 
Medicine, Universitas Padjadjaran (number 
208) and Dr. Hasan Sadikin General Hospital, 
Bandung, Indonesia (number 3002).
Table 1 Characteristics of MDR TB Patients
Characteristics of MDR TB Patients Number of Patients n=142Gender      Male 81 (57%)    Female 61 (43%)
Age (Years old)  
    Median  (SD) 36 (12.565)
    Range 15–71Comorbid 11 (8%)    Diabetes mellitus 2 8 (5%)    Chronic hepatitis 1 (1%)
    Lupus and pregnant 1 (1%)
    HIV 1 (1%)No Comorbid 110 (77%)No Data 21 (15%)Current Condition      Still in therapy at  Dr. Hasan Sadikin General Hospital 94 (66%)    Died 27 (19%)    Drop Out 13 (9%)
    Become XDR TB 7 (5%)
    Reffered to other Hospital 1 (1%)
Notes: HIV=Human Immunodeficiency Virus; SD=Standard Deviation; XDR TB=Extremely Drugs Reistant Tuberculos
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Results
Half of patients (57%) were male, with median 
age 36. Among 142 patients, 110 (77%) patients had no comorbid. The majority of 
patients (66%) were still in therapy of MDR TB at Dr. Hasan Sadikin General Hospital 
(Table 1).
Among 142 patients, 96% of them had previous history of tuberculosis therapy. The 
majority of them (81%) still had positive AFB sputum on 5th month or more during previous category 2 tuberculosis therapy, at early 
diagnosis. Rarely, one (1%) patients had no 
history of tuberculosis therapy (Table 2).
Majority patients (70, 49%) used regimen 
Figure 1 Regimen MDR TB Therapy and Its Modification During Therapy
Table 2 Clinical Characteristics of MDR TB Patients 
Clinical Characteristics 
(at Early Diagnosis)
Number of Patients (%) 
n=142History of Previous TB Therapy 137 (96%)    Sputum that still remained positive AFB during previous category 2 TB therapy at     5th month or more 80 (56%)    Sputum that still remained positive AFB during previous  category 2 TB therapy at     3rd month or more 19 (13%)    Sputum that still remained positive AFB during previous category 1 TB therapy at     5th month or more 15 (11%)
    Relapse case (category 1 or 2) 14 (10%)    Default case 6 (4%)
    Sputum that still remained positive AFB during previous category 1 with additional     a month TB therapy 2 (1%)
    History of TB therapy for >1 month in non-DOTS facility, using second line regimen, 
    such as fluoroquinolone and kanamycin.
1 (1%)No History of TB Therapy 1 (1%)
    Close contact to MDR TB patients 1 (1%)No Data 4 (3%)
Notes: TB=Tuberculosis; AFB=Acid Fast Bacilli; MDR TB=Multidrug Resistant Tuberculosis; DOTS=Directly Observed 
Treatment Short-Course 
Notes: Z=Pyrazinamide; Km=Kanamycin; Lfx=Lefofloxacin; Eto=Ethionamide; Cs=Cycloserine; Cm=Capreomycin; 
             E=Ethambutol; PAS=P-aminosalycilate acid
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therapy of Z-Cm-Lfx-Eto-Cs. From  142 patients, 
10 (7%) patients did not have any written data regarding regimen therapy on medical records. 
Few (4%) patients had regimen modification 
(Figure 1).
All patients (100%) experienced side effects during therapy. The most common side effects 
were gastroenteropathy, rheumatism and 
headache in 113 patients (79%). Among 113 
patients that experienced gastroenteropathy 
and rheumatism, 64 of them used Z-Cm-Lfx-
Eto-Cs. One (1%) patient had experienced 
tentamen suicide and it was the most severe 
side effect of MDR TB therapy (Table 3).
Few patients experienced other side effects 
of MDR TB therapy. Less than 10% patients 
experienced hematologic abnormalities 
(leucopenia and thrombocytopenia), visual 
disorder, vertigo, epilepsy, etc (Table 4).
Discussion
This study discovered that most of MDR TB patients had history of TB therapy, the majority 
of them still experienced positive AFB sputum on 5th month or more during previous category 2 TB therapy, at early diagnosis. All patients 
experienced side effects from MDR TB therapy, 
while the most common side effects were gastroenteropathy, rheumatism and headache. 
Gastroenteropathy was manifested by 
nausea, vomit, anorexia, diarrhoea, dan other 
gastric-enteric disturbance. All patients used 
combination of pyrazinamide, levofloxacin, ethionamide and cycloserine. In addition to 
that, 49% patients used capreomycin and 42% patients used kanamycin in their combination 
regimen therapy. It was the first study in Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. 
Other common side effects were 
hyperuricemia, nephrotoxicity, audiometric abnormality, hypothyroidism and drug 
induced liver intoxination. Manifestations of 
drug induced liver intoxination were fatigue, 
nausea, vomit, anorexia, fever and abdominal 
pain through anamnesis that were written on 
medical records. Elevation of creatinin and ureum monitored routinely to evaluate side 
effect of nephrotoxicity. Some patients also 
experienced psychiatric status abnormality. 
In this study, a patient experienced tentamen 
suicide and it was the most severe side effects 
of therapy. Few patients experienced regimen 
modification by stopping or adding regimen to their therapy.
In line with this study,  a study conducted by Tarek et al.8 showed that prevalence 
of retreatment case was 97.3%, while the 
remaining were new cases. Based on World 
Health Organization (WHO) surveillance research data,1 15% of patients had history 
Table 3 Most Common Side Effects of MDR TB Therapy
Side Effects
Regimen
Z Km Lfx Eto Cs 
(n=60)
Z Cm Lfx Eto Cs 
(n=70)
E Z Km Lfx Eto Cs
(n=3)
Gastro-enteropathy (n=113) 47 (42%) 64 (57%) 2 (2%)
Rheumatism (n=113) 49 (43%) 64 (57%) 2 (2%)
Headache (n=113) 48 (42%) 63 (56%) 2 (2%)
Hyperuricemia (n=71) 29 (41%) 42 (59%) 0 (0%)
Hypokalemia (n=67) 26 (39%) 39 (58%) 2 (3%)
Audiometry Abnormality (n=49) 26 (53%) 21 (43%) 2 (4%)
Nephrotoxicity
   Ureum (n=35) 13 (37%) 21 (60%) 1 (3%)
   Creatinine (n=25) 11 (44%) 13 (52%) 1 (4%)
Pain at site of  injection (n=25) 8 (32%) 16 (64%) 1 (4%)
Psychiatric Status Abnormality (n=26) 12 (46%) 14 (54%) 0 (0%)
Tentamen suicide (n=1) 0 (0%) 1 (1%) 0 (0%)
Hypothyroidism (n=21) 9 (43%) 12 (57%) 0 (0%)
Notes: Z=Pyrazinamide; Km=Kanamycin; Lfx=Lefofloxacin; Eto= Ethionamide; Cs=Cycloserine; Cm=Capreomycin;               E=Ethambutol
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of TB therapy and 3% of patients were new 
case. This study showed that 1% patient 
had no history TB therapy. Specifically, new 
case is caused by close contact to MDR TB 
patients (infected by patients).5 According to 
previous study, there were 36% of patients 
still experienced positif AFB sputum during 5th month or more of category 2 TB therapy usage 
and 32% of patients experienced relapse case.1 
It is different from this study whereas fewer 
(10%) of patients were experienced relapse.  
These findings were caused by man 
made phenomenon, which did not follow 
standardized therapy appropriately. The 
reason were multifactorial, included patients 
factor (mostly by uncompliance case, human 
immunodeficiency virus/ HIV patient), health 
care facilitators factors (quality of DOTS implementation, access to diagnosing and 
therapy), and regimen factors (quality of 
regimen, determination of regimen dose).5,9,10 In this study, the side effects of therapy 
was similar to the previously study by 
Munawwarah et al.11 that 100% of MDR TB patients had side effects. From surveillance data WHO 2011 research, the most common 
side effects were nausea/vomit (32.8%)1 
, followed by arthralgia (16.4%), hearing 
disturbance (12%), headache (1.7%) and 
electrolyte disturbance (11.5%).1Inappropriate dosage played important role that contributed to side effects of 
MDR TB patients.1 From result findings, 
rheumatism was manifested with arthralgia, myalgia, gout arthritis through anamnesis and hyperuricemia through laboratory 
examination. Pyrazinamide has 2 main 
side effects: drug induced liver intoxication 
dan gout-like arthralgia (manifested by 
rheumatism and hyperuricemia).1,12,13
Persistent nausea and vomit were caused 
by ethionamide or p-aminosalicylic acid 
(PAS), whereas transient nausea & vomit were 
caused by pyrazinamide.14,15 Gastrointestinal 
Table 2 Clinical Characteristics of MDR TB Patients 
Side Effects Number of Patients (n=142)Anemia 17 (12%)Insomnia 17 (12%)Fatigue  17 (12%)
Lymphocytopenia 15 (11%)
Drug Induced Liver Injury   SGOT 13 (9%)    SGPT 2 (1%)Peripheral Neuropathy 14 (10%)
Skin Inflamation Manifestation 12 (8%)Fever 11 (8%)
Leukocytosis 7 (5%)Thrombocytosis 6 (4%)Palpitation 4 (3%)
Visual Disorder 4 (3%)Dehydration 4 (3%)
Vertigo 3 (2%)
Leukopenia 2 (1%)
Cardiac Rhythm Abnormality 2 (1%)Thrombocytopenia 1 (1%)
Epilepsy 1 (1%)Taste and Smell Abnormality 1 (1%)Polycythemia Sekunder 1 (1%)Metabolic Acidosis 1 (1%)
Notes: SGOT=Serum Glutamic-Oxaloacetic Transaminase, SGPT=Serum Glutamic-Pyruvic Transaminase 
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disturbance can be caused by levofloxacin.1 
Meanwhile, pyrazinamide can cause headache, but chronic headache can be probably caused by cycloserine. Headache also can be caused 
by levofloxacin.1
In this study, some patients experienced 
electrolyte imbalance, specifically hypokalemia. Hypokalemia can be caused by 
injecting drugs (capreomycin), vomit, diarrhea and other causes.15 Patients were usually manifested by fatigue, palpitation, paresthesia, 
muscle cramp and numbness. Nephrotoxicity 
can be seen through laboratory examination of ureum and creatinine.15 Injecting drugs, such 
as kanamycin (frequently) and cycloserine, can have direct effect on kidney, that can cause electrolyte imbalance.13 Capreomycin and kanamycin can cause auditory abnormality.1,16 According to Reviono et al.17 that 57.6% of MDR TB patients 
experienced hearing disturbance. Out of them, 
54.2% used kanamycin. Cycloserine can affect psychiatric status of 
patients, that manifested as depression, anxiety 
or psychosis (hallucination, delirium).13,14,16 High level of TSH can be caused by ethionamide and PAS combination.18,19 
Few patients had other side effects during 
MDR TB therapy. Visual disorder can be caused by ethionamide. On the other hand, the most common side effect of ethambutol is neuritis opticus.13 Therefore, patients should 
be monitored by visual acquity test monthly. 
Rarely, levofloxacin can cause leukopenia and 
eosinophillia in <1% patients.1 The PAS also causes thrombocytopenia, agranulocytosis, leukopenia and hemolytic anemia.14
Patients had baseline examinations before 
MDR TB therapy was started. The baseline 
examinations were laboratorium examination 
(blood test, urine macroscopic and 
microscopic test), rontgen, audiometric test, psychiatric status test, thyroid function test, etc.1,14 There were also several examinations 
for follow up the patients during MDR TB 
therapy routinely. Those examinations were 
rontgen, laboratorium examination (blood and 
urine), thyroid function test, audiometric test, psychiatric status test, etc.1,6,8 By those baseline 
examinations and follow up examinations routinely, physicians can evaluate condition 
of patients, whether side effects and its 
management or regimen modification during therapy.14
The therapy modifications depend on severity of patients’s condition. It can be 
caused by some condition, such as non-
tolerated side effects or new drug resistant.1 
Usage of kanamycin can be stopped if the 
side effects are worsened, for example severe 
ototoxicity or nephrotoxicity. Ototoxicity 
can be observed monthly by follow up and 
audiometric test, while nephrotoxicity can be monitored by creatinine level. Kanamycin also can cause vertigo. Usage of ethionamide can 
be stopped if the side effects are worsened, for 
example severe nausea and vomit, that leads to dehydration. Monitoring electrolyte is needed in this case. Capreomycin is indicated, if there 
is no improvement (resistant) to kanamycin, based on DST result.20 The PAS has well-tolerated and no cross resistance. Data about baseline and clinical characteristics, regimen and mainly side effects 
of MDR TB patients were still not completely 
written in medical records.This condition was the limitation of this study.  
In conclusion, most of MDR TB patients in Dr. Hasan Sadikin General Hospital had previous history of tuberculosis therapy. The 
majority of them still experienced positive AFB sputum on 5th month or more during previous category 2 tuberculosis therapy, at early diagnosis. The majority of patients used 
combination of pyrazinamide, capreomycin, 
levofloxacin, ethionamide and cycloserine. The majority of them had gastroenteropathy 
and rheumatism. All patients experienced 
side effects during MDR TB therapy. The most 
common side effects were gastroenteropathy, rheumatism and headache. The most severe 
side effect was tentamen suicide. Few patients 
had regimen modification during therapy depends on their condition for better therapy outcomes.In this secondary data based survey, 
complete written findings of status patients 
during therapy by health care facilitators were needed to evaluate patient condition. By that process, updates of research data regarding 
MDR TB can be achived to monitor the effectivity of therapy. Further study needed 
to be conducted for evaluation of MDR TB patients, either by primary and secondary data collection.
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